Neurology Clinical Development Updates: Immunovant designed the batoclimab MG trial to study the potential benefits of batoclimab across three important patient needs that we do not believe are addressed by other FcRn inhibitor MG development programs: 1) the potential benefits of high dose induction therapy, 2) continuous long-term therapy with a simple subcutaneous injection, and 3) multiple doses to potentially enable tailored, continuous therapy based on individual patient needs. Given the importance of ...

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2024. "We are very excited about the immunology market evolution that we believe positions the anti-FcRn mechanism to be the leading therapeutic class across a broad range of autoantibody-driven indications. Within the ...

Biohaven (BHVN) stock crashed Wednesday after the company's experimental protein-degrading drug — which could be used to treat a myriad of immune-related diseases — lagged investor expectations. X The company tested four doses of its drug, BHV-1300, which is meant to break down immunoglobulin G, or IgG, an autoantibody at the center of diseases like rheumatoid arthritis and myasthenia gravis. In healthy volunteers, the doses reduced IgG by up to 37%. Biohaven called the results "positive," noting that IgG l ...

Shares of Immunovant, Inc. (IMVT) have gained 0.1% over the past four weeks to close the last trading session at $29.39, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $49.56 indicates a potential upside of 68.6%. The average comprises 16 short-term price targets ranging from a low of $32 to a high of $57, with a standard deviation of $6.11. While the lowest estimate indicates ...

Immunovant, Inc. (IMVT) is a New York-based biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. The company currently has no marketed products in its commercial portfolio.Immunovant’s clinical-stage pipeline comprises its lead product candidate, batoclimab (formerly known as IMVT-1401), and a new candidate, IMVT-1402, which are being developed as a subcutaneous injection for the treatment of IgG-mediated autoimmune diseases.Let’s delve deeper to discuss ...

Investors might want to bet on Immunovant, Inc. (IMVT) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual inves ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 83-2771572 (State or other jurisdiction of incorporati ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 IMMUNOVANT, INC. (Exact name of Registrant as specified in its Charter) Delaware 83-2771572 (State or other jurisdiction of incorporat ...

IMMUNOVANT 2 | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------|------------|-------|-------|-------| | | | | | | | What we do: | | | | | | We are developing targeted therapies that are designed to address the complex and variable needs of people with autoimmune diseases. | | | | | | | | | | | | Love Trailblazing | All Voices | | | | autoimmune disease indications Differentiated product can ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Excha ...